Free Submission Public Relations &
Deutsch English


New Market Report: Tabalumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Print article Print article
2013-12-10 13:48:04 - New Pharmaceuticals market report from GlobalData: "Tabalumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022"

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

Eli Lilly and Company is developing tabalumab for the treatment of lupus. Tabalumab is a fully human immunoglobulin G subclass 4 (IgG4) monoclonal antibody, which binds and neutralizes both soluble and membrane-bound

BLyS (also known as BAFF).

Full Report Details at
- ..


* Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Tabalumab including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Tabalumab for the top seven countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Tabalumab performance
* Obtain sales forecast for Tabalumab from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Prognosis
3.3 Quality of Life
3.4 Symptoms
4 Disease Management
4.1 Diagnosis Overview
4.1.1 SLE Diagnosis
4.1.2 LN Diagnosis
4.2 Treatment Overview
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Efficacious Treatments with Reduced Side Effects
6.2.2 Management of LN
6.2.3 Improvement in Patients' Mortality
6.2.4 Management of Lupus Comorbidities
6.2.5 Sensitive and Reliable Biomarkers
6.2.6 Physicians' Education and Public Awareness of SLE
6.2.7 Unmet Needs Gap Analysis
6.3 Opportunities
6.3.1 Efficacious and Safe Therapies
6.3.2 Therapies Targeting LN Patients
6.3.3 Treatments for Common Lupus Comorbidities
6.3.4 Discovery of Biomarkers
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
8 Tabalumab
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
8.9 Forecast
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed SLE and LN Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 General Pricing Assumptions
9.4.4 Generic Erosion
9.4.5 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analysts
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms of SLE
Table 2: 1997 Updated ACR Criteria for Classification of SLE
Table 3: The SLICC Clinical and Immunologic Criteria for Classification of SLE
Table 4:WHO and ISN/RPS classifications of LN
Table 5: Treatment Guidelines for SLE and LN
Table 6: Most Prescribed Drugs for SLE and LN by Class in the Global Markets, 2013
Table 7: Leading Treatments for SLE and LN, 2013
Table 8: Overall Unmet Needs in SLE and LN - Current Level of Attainment
Table 9: Clinical Unmet Needs in SLE and LN - Gap Analysis, 2013
Table 10: SLE and LN - Phase Pipeline, 2013
Table 11: Comparison of Therapeutic Classes in Development for SLE and LN, 2013
Table 12: Product Profile - Tabalumab (LY-2127399)
Table 13: Tabalumab SWOT Analysis, 2013
Table 14: Global SLE Sales Forecasts ($m) for Tabalumab, 2012-2022
Table 15: Global LN Sales Forecasts ($m) for Tabalumab, 2012-2022
Table 16: Number of Physicians Surveyed by Country

List of Figures

1.2 List of Figures
Figure 1: Overview of the Etiology and Pathogenesis of SLE
Figure 2: Overview of the BAFF/APRIL Ligand and Receptor System
Figure 3: Overview of the Treatment Management of SLE
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in SLE and LN, 2012-2022

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact